A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:

2000

Contact PI Name:

David Morgan

Contact PI Affiliation:

Department of Pharmacology, Alzheimer Research Laboratory, University of South Florida, Tampa, Florida USA

Co-Authors:

David M. Diamond, Paul E. Gottschall, Kenneth E. Ugen, Chad Dickey, John Hardy, Karen Duff, Paul Jantzen, Giovanni DiCarlo, Donna Wilcock, Karen Connor, Jaime Hatcher, Caroline Hope, Marcia Gordon, Gary W. Arendash

Primary Reference (PubMED ID):

11140686

Funding Source:

Benjamin Research Trust

University of South Florida Research Foundation

National Institute on Aging (NIA)

National Heart Lung and Blood Institute (NHLBI)

National Institute of Allergy and Infectious Disease (NIAID)

Study Goal and Principal Findings:

In this study the authors showed that vaccination with Abeta peptide 42 protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease. The Abeta-vaccinated mice also had a partial reduction in the beta amyloid burden at the end of the study. This therapeutic approach may thus prevent and, possibly treat Alzheimer's dementia.

Bibliographic Notes:

Erratum in: Nature 2001 Aug 9;412(6847):660.

Therapeutic Agent

Therapeutic Information:

Therapy Type:

Biologic - Immunotherapy(active)

Therapeutic Agent:

beta Amyloid Peptide

PubMed

ClinicalTrials

Patents

Therapeutic Target:

beta Amyloid Peptide

Open Targets

Pharos

Agora

Animal Model

Model Information:

Species:

Mouse

Model Type:

APPxPS1

Model Name:

PS/APP

ALZFORUM

Strain/Genetic Background:

Mixed Background of C57B6/SJL and Swiss Webster/B6D2F1

Experimental Design

Is the following information reported in the study?:

Power/Sample Size Calculation

Randomized into Groups

Blinded for Treatment

Blinded for Outcome Measures

Pharmacokinetic Measures

Pharmacodynamic Measures

Toxicology Measures

ADME Measures

Biomarkers

Dose

Formulation

Route of Delivery

Duration of Treatment

Frequency of Administration

Age of Animal at the Beginning of Treatment

Age of Animal at the End of Treatment

Sex as a Biological Variable

Study Balanced for Sex as a Biological Variable

Number of Premature Deaths

Number of Excluded Animals

Statistical Plan

Genetic Background

Inclusion/Exclusion Criteria Included

Conflict of Interest

Outcomes

Outcome Measured

Outcome Parameters

Behavioral

Radial Arm Water Maze

Histopathology

beta Amyloid Load

Immunology

Anti-beta Amyloid Peptide 42 Antibody Titers

Print: